Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arf-GAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2) is a multidomain protein encoded by the *ACAP2* gene in humans and is a member of the centaurin beta family. It functions primarily as an enzyme—specifically a GTPase-activating protein (GAP) for the small GTPase ARF6—participating in the inactivation of ARF6 by enhancing its intrinsic GTPase activity. ACAP2 contains a coiled-coil domain (involved in protein-protein interactions and oligomerization), ankyrin repeats (often mediating protein binding), and a PH (pleckstrin homology) domain that binds specific phosphoinositides in membranes[1][3][6][7][9][11]. ACAP2 binds to the plasma membrane and participates in actin cytoskeleton regulation and membrane trafficking; it also directly interacts with RAB35 through its ankyrin repeats but does not have GAP activity for RAB35[2][9][11]. ACAP2 shows pro-apoptotic activity in cancer cell lines, and its down-regulation has been reported in various human cancers, suggesting a tumor suppressor role[4]. No approved drugs directly target ACAP2, and there are no established clinical biomarkers or safety profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arf-GAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2).